The status of high-dose chemotherapy with hematopoietic stem cell transplantation in patients with germ cell tumor

Ugo De Giorgi, Giovanni Rosti, Giorgio Papiani, Maurizio Marangolo

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background and Objectives. Germ cell tumors (GCTs) are very chemosensitive cancers, in which high-dose chemotherapy (HDCT) has been investigated as salvage therapy or as first-line treatment in poor prognosis patients. This paper presents an update of available information in order to define the status of HDCT in GCT patients. Information sources. The authors have been working in this field, contributing to international clinical trials and to peer-reviewed journals with original papers. The material examined in this review includes articles published in journals covered by MedLine®, reviews from journals with high impact factor, and unpublished data from the European Group for Blood and Marrow Transplantation (EBMT) registry. State of the Art and Perspectives. The delineation of prognostic factors associated with a poor probability of survival after HDCT contributed to the selection of patients who are likely to get an advantage from HDCT and those who should be spared from dose-intensive treatment. HDCT as first-line therapy for poor prognosis GCT (IGCCCG classification), and in a salvage setting in good risk GCT (prognostic index from Beyer et al.), has been associated with a very high rate of complete remissions and long-term disease-free survivors. However, it is important to wait for the results of ongoing randomized trials for the validation of these findings. Other strategies are required for patients with refractory GCTs. Several new treatment options are currently emerging for this subset of patients.

Original languageEnglish
Pages (from-to)95-104
Number of pages10
JournalHaematologica
Volume87
Issue number1
Publication statusPublished - 2002

Fingerprint

Germ Cell and Embryonal Neoplasms
Hematopoietic Stem Cell Transplantation
Drug Therapy
Salvage Therapy
Therapeutics
Patient Selection
Survivors
Registries
Clinical Trials
Survival
Neoplasms

Keywords

  • Germ cell tumor
  • Hematopoietic stem cell transplantation
  • High-dose chemotherapy
  • Review

ASJC Scopus subject areas

  • Hematology

Cite this

The status of high-dose chemotherapy with hematopoietic stem cell transplantation in patients with germ cell tumor. / De Giorgi, Ugo; Rosti, Giovanni; Papiani, Giorgio; Marangolo, Maurizio.

In: Haematologica, Vol. 87, No. 1, 2002, p. 95-104.

Research output: Contribution to journalArticle

De Giorgi, Ugo ; Rosti, Giovanni ; Papiani, Giorgio ; Marangolo, Maurizio. / The status of high-dose chemotherapy with hematopoietic stem cell transplantation in patients with germ cell tumor. In: Haematologica. 2002 ; Vol. 87, No. 1. pp. 95-104.
@article{e06e450495ab45f995a18b45b0778769,
title = "The status of high-dose chemotherapy with hematopoietic stem cell transplantation in patients with germ cell tumor",
abstract = "Background and Objectives. Germ cell tumors (GCTs) are very chemosensitive cancers, in which high-dose chemotherapy (HDCT) has been investigated as salvage therapy or as first-line treatment in poor prognosis patients. This paper presents an update of available information in order to define the status of HDCT in GCT patients. Information sources. The authors have been working in this field, contributing to international clinical trials and to peer-reviewed journals with original papers. The material examined in this review includes articles published in journals covered by MedLine{\circledR}, reviews from journals with high impact factor, and unpublished data from the European Group for Blood and Marrow Transplantation (EBMT) registry. State of the Art and Perspectives. The delineation of prognostic factors associated with a poor probability of survival after HDCT contributed to the selection of patients who are likely to get an advantage from HDCT and those who should be spared from dose-intensive treatment. HDCT as first-line therapy for poor prognosis GCT (IGCCCG classification), and in a salvage setting in good risk GCT (prognostic index from Beyer et al.), has been associated with a very high rate of complete remissions and long-term disease-free survivors. However, it is important to wait for the results of ongoing randomized trials for the validation of these findings. Other strategies are required for patients with refractory GCTs. Several new treatment options are currently emerging for this subset of patients.",
keywords = "Germ cell tumor, Hematopoietic stem cell transplantation, High-dose chemotherapy, Review",
author = "{De Giorgi}, Ugo and Giovanni Rosti and Giorgio Papiani and Maurizio Marangolo",
year = "2002",
language = "English",
volume = "87",
pages = "95--104",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "1",

}

TY - JOUR

T1 - The status of high-dose chemotherapy with hematopoietic stem cell transplantation in patients with germ cell tumor

AU - De Giorgi, Ugo

AU - Rosti, Giovanni

AU - Papiani, Giorgio

AU - Marangolo, Maurizio

PY - 2002

Y1 - 2002

N2 - Background and Objectives. Germ cell tumors (GCTs) are very chemosensitive cancers, in which high-dose chemotherapy (HDCT) has been investigated as salvage therapy or as first-line treatment in poor prognosis patients. This paper presents an update of available information in order to define the status of HDCT in GCT patients. Information sources. The authors have been working in this field, contributing to international clinical trials and to peer-reviewed journals with original papers. The material examined in this review includes articles published in journals covered by MedLine®, reviews from journals with high impact factor, and unpublished data from the European Group for Blood and Marrow Transplantation (EBMT) registry. State of the Art and Perspectives. The delineation of prognostic factors associated with a poor probability of survival after HDCT contributed to the selection of patients who are likely to get an advantage from HDCT and those who should be spared from dose-intensive treatment. HDCT as first-line therapy for poor prognosis GCT (IGCCCG classification), and in a salvage setting in good risk GCT (prognostic index from Beyer et al.), has been associated with a very high rate of complete remissions and long-term disease-free survivors. However, it is important to wait for the results of ongoing randomized trials for the validation of these findings. Other strategies are required for patients with refractory GCTs. Several new treatment options are currently emerging for this subset of patients.

AB - Background and Objectives. Germ cell tumors (GCTs) are very chemosensitive cancers, in which high-dose chemotherapy (HDCT) has been investigated as salvage therapy or as first-line treatment in poor prognosis patients. This paper presents an update of available information in order to define the status of HDCT in GCT patients. Information sources. The authors have been working in this field, contributing to international clinical trials and to peer-reviewed journals with original papers. The material examined in this review includes articles published in journals covered by MedLine®, reviews from journals with high impact factor, and unpublished data from the European Group for Blood and Marrow Transplantation (EBMT) registry. State of the Art and Perspectives. The delineation of prognostic factors associated with a poor probability of survival after HDCT contributed to the selection of patients who are likely to get an advantage from HDCT and those who should be spared from dose-intensive treatment. HDCT as first-line therapy for poor prognosis GCT (IGCCCG classification), and in a salvage setting in good risk GCT (prognostic index from Beyer et al.), has been associated with a very high rate of complete remissions and long-term disease-free survivors. However, it is important to wait for the results of ongoing randomized trials for the validation of these findings. Other strategies are required for patients with refractory GCTs. Several new treatment options are currently emerging for this subset of patients.

KW - Germ cell tumor

KW - Hematopoietic stem cell transplantation

KW - High-dose chemotherapy

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=0036157215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036157215&partnerID=8YFLogxK

M3 - Article

C2 - 11801470

AN - SCOPUS:0036157215

VL - 87

SP - 95

EP - 104

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 1

ER -